Lung cancer trials in Spain

In Spain 273 Also abroad 2733

273 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Where
Barcelona, Logrono, Lugo, Madrid, Málaga, Valencia
Age
18 years and over
People
243 worldwide
Run by
Shanghai Henlius Biotech
See details and how to joinNCT06907615 · EU 2025-523803-31-00
Phase 2Taking people
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Where
Barcelona, Jerez de la Frontera, L'Hospitalet de Llobregat, Madrid, Sevilla
Age
18 years and over
People
180 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07221474 · EU 2025-520902-37-00
Phase 1/2Taking people
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Where
Barcelona, L'Hospitalet de Llobregat, Pozuelo de Alarcón, Sevilla
Age
18 years and over
People
140 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07286149 · EU 2024-512248-47-00
Phase 3Taking people
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Where
A Coruña, Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Málaga, Sevilla
Age
18 years and over
People
450 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00
Phase 1Taking people
A Study of PHN-012 in Patients With Advanced Solid Tumors
Where
Barcelona, Madrid, Valencia
Age
18 years and over
People
165 worldwide
Run by
Pheon Therapeutics
See details and how to joinNCT07127874
No phaseTaking people
OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain
Where
A Coruña, Alicante, Barcelona, C Rdoba, El Palmar, Girona, Granada, Jaén, Las Palmas de Gran Canaria, León, Lleida, Madrid, Málaga, Ourense, Palma, Sabadell, Salamanca, Santa Cruz de Tenerife, Santander, Santiago de Compostela, Seville, Valencia, Valladolid, Vigo, Zaragoza
Age
18 years and over
People
500
Run by
AstraZeneca
See details and how to joinNCT06068049
Phase 3Taking people
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Where
A Coruna, Barcelona, Elche, Jerez de la Frontera, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Málaga, Palma, Sevilla, Valencia
Age
18 years and over
People
714 worldwide
Run by
Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Where
Badajoz, Badalona, Barcelona, Castello De La Plana, Jaén, Lugo, Madrid, Málaga, Oviedo, Palma, Valencia, Vigo, Zaragoza
Age
18 years and over
People
830 worldwide
Run by
AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00
Phase 1Taking people
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Pozuelo de Alarcón, Valencia
Age
18 years and over
People
45 worldwide
Run by
Theras Inc.
See details and how to join2024-512515-45-01 · EU 2024-512515-45-01
Phase 1/2Taking people
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Where
A Coruña, Barcelona, Madrid
Age
12 years and over
People
359 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00
Phase 1/2Taking people
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Where
Barcelona, Hospitalet, Madrid, Majadahonda, Málaga, Santiago de Compostela, Seville, Valencia
Age
18 years and over
People
416 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06618287
Phase 3Taking people
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Where
Barcelona, Madrid, Majadahonda
Age
18 years and over
People
531 worldwide
Run by
AbbVie
See details and how to joinNCT07365241 · EU 2025-523819-11-00
Phase 1Taking people
A study of Daraxonrasib (RMC-6236) in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B
Where
A Coruña, Badalona, Barcelona, Madrid, Málaga, Pamplona, Sevilla, Valencia
Age
18 years and over
People
180 worldwide
Run by
Revolution Medicines Inc.
See details and how to join2023-509572-42-00 · EU 2023-509572-42-00
Phase 1/2Taking people
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Where
Barcelona, Madrid, Pamplona, Seville, Valencia, Zaragoza
Age
18 years and over
People
534 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06128551
Phase 1Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
Where
Madrid
Age
18 years and over
People
232 worldwide
Run by
AbbVie
See details and how to joinNCT06858813 · EU 2024-518012-39-00
Phase 1Taking people
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Where
Barcelona, Madrid
Age
18 years to 100 years
People
116 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00
Phase 1Taking people
A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti–PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
Where
Barcelona, Madrid, Pamplona, Pozuelo de Alarcón
Age
18 years and over
People
93 worldwide
Run by
Gilead Sciences Inc.
See details and how to joinNCT05007782 · EU 2022-501684-40-00
Phase 1Taking people
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Where
Barcelona, Madrid, Piqueras, Seville
Age
18 years and over
People
540 worldwide
Run by
SystImmune Inc.
See details and how to joinNCT05983432
Phase 2Taking people
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
Where
Alicante, Barcelona, Majadahonda
Age
18 years and over
People
48 worldwide
Run by
ETOP IBCSG Partners Foundation
See details and how to joinNCT07203053 · EU 2025-522288-13-00
Phase 1/2Taking people
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Where
Barcelona, Madrid, Pamplona, Pozuelo de Alarcón
Age
18 years and over
People
265 worldwide
Run by
Blueprint Medicines Corporation
See details and how to joinNCT07629960
Phase 3Taking people
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Where
A Coruna, Badajoz, Badalona, Barakaldo, Barcelona, Burgos, Girona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Lugo, Madrid, Málaga, Marbella, Oviedo, Santander, Sevilla, Valencia, Valladolid, Zaragoza
Age
18 years and over
People
780 worldwide
Run by
Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Sevilla, Valencia
Age
18 years and over
People
182 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06855771 · EU 2024-519814-29-00
Phase 1/2Taking people
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Where
Badajoz, Badalona, Barcelona, Girona, Madrid, Manresa, Seville, Valencia
Age
18 years and over
People
118 worldwide
Run by
MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07407933
Phase 1Taking people
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
Where
Barcelona, L'Hospitalet de Llobregat
Age
18 years and over
People
62 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521702-18-00 · EU 2025-521702-18-00
Phase 3Taking people
Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
Where
A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga, Valencia
Age
18 years and over
People
168 worldwide
Run by
Amgen Inc.
See details and how to join2026-525489-23-00 · EU 2026-525489-23-00